Efficacy and Safety of Intravitreal Fluocinolone Acetonide Implant for Chronic Diabetic Macular Edema Previously Treated in Real-Life Practice: The REALFAc Study
Diabetic macular edema (DME) is the main cause of visual impairment in diabetic patients and a chronic disease requiring long-term treatments. The fluocinolone acetonide (FAc) implant has recently been approved to treat DME in patients considered insufficiently responsive to available therapies. Thi...
Main Authors: | Thibaud Mathis, Maxence Papegaey, Cécile Ricard, Amina Rezkallah, Frédéric Matonti, Aditya Sudhalkar, Cristina Vartin, Corinne Dot, Laurent Kodjikian |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-03-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/14/4/723 |
Similar Items
-
Management of Patients with Diabetic Macular Edema Switched from Dexamethasone Intravitreal Implant to Fluocinolone Acetonide Intravitreal Implant
by: Stéphanie Baillif, et al.
Published: (2022-11-01) -
Preserflo Microshunt Surgery for Ocular Hypertension following Intravitreal Fluocinolone Acetonide Implant Removal: A Case Report
by: Amina Rezkallah, et al.
Published: (2022-12-01) -
Efficacy and safety of sustained-delivery fluocinolone acetonide intravitreal implant in patients with chronic diabetic macular edema insufficiently responsive to available therapies: a real-life study
by: Massin P, et al.
Published: (2016-07-01) -
Real-World Efficacy and Safety of Fluocinolone Acetonide Implant for Diabetic Macular Edema: A Systematic Review
by: Laurent Kodjikian, et al.
Published: (2021-01-01) -
Intravitreal methotrexate and fluocinolone acetonide implantation for Vogt-Koyanagi-Harada uveitis
by: Jong G. Park, et al.
Published: (2020-09-01)